Analysis of EuroTARGET cohort data will contribute to personalization of therapy for patients with mRCC. The extensive clinical data and multiplatform EuroTARGET data will be freely available.

No abstract

micropapilar (CMP) es una variante anatomopatológica infrecuente de carcinoma vesical de comportamiento agresivo. Se presenta habitualmente como carcinoma de alto grado, en estadios avanzados y asociado a otras formas histológicas en proporciones variables. No manifiesta signos clínicos diferenciales con el carcinoma vesical típico. Los estudios de marcadores moleculares son todavía contradictorios. El tratamiento debería ser precoz y agresivo, fundamentalmente quirúr-gico, dado que la Radioterapia y la Quimioterapia han demostrado escasa eficacia hasta el momento.Presentamos el caso de un varón de 72 años con síntomas miccionales de larga evolución y hematuria macroscópica de reciente aparición que se diagnosticó de CMP en estadio avanzado. Al año de la cistectomía radical asociada a quimioterapia con carboplatino y gemcitabina se evidenció progresión rápida de la enfermedad y falleció a los 14 meses.Palabras clave: Vejiga. Carcinoma transicional. Carcinoma micropapilar. ABSTRACT MICROPAPILLARY CARCINOMA OF THE BLADDER: CASE REPORT AND REVIEWOF THE LITERATURE Micropapillary carcinoma is an uncommon pathologic variant of bladder carcinoma with aggressive behavior. Its usual presentation is like a high grade and high stage carcinoma and associated with other histologic types in different proportion. It doesn´t differ clinically from normal transitional cell carcinoma of the bladder. Studies of molecular markers are still contradictories. Treatment should be early and aggresive, based on surgical therapy as radiotherapy and chemotherapy have shown limited results.We report a 72 years old man suffering from low urinary tract symptoms for years and recently presented gross hematuria. He was diagnosed as high stage micropapillary carcinoma. One year after radical cystectomy and subsequent chemotherapy based on carboplatin and gemcitabine , progression of the disease was shown on CT and the patient died 14 months after the diagnosis.

Peutz-Jeghers syndrome is an autosomal dominant condition characterized by the association of hamartomatous polyps in the digestive tract, mucocutaneous pigmentation, family history, and infrequently tumors of the female genital tract with one of the most characteristic being the gastric-type endocervical adenocarcinoma. We present the case of a 75-year-old woman with a history of gastrointestinal polyps and cancer of the pancreas and breast, diagnosed with Peutz-Jeghers syndrome, who clinically debuted with a primary adnexal tumor. However, on histologic examination it was found to be a gastric-phenotype primary mucinous carcinoma tubal in origin, associated to tubal mucinous metaplasia and secondary ovarian involvement. One of her daughters had a confirmed genetic diagnosis of Peutz-Jeghers syndrome and presented with mucinous metaplasia of the tubal mucosa in the pathological study of a prophylactic hysterectomy specimen. Another of her daughters died from an ovarian juvenile granulosa cell tumor, she did not have a genetic diagnosis of Peutz-Jeghers syndrome. This case intends to highlight the rarity of gastrointestinal-type mucinous carcinomas of the ovary and fallopian tube (similar to gastric-type endocervical adenocarcinoma) in Peutz-Jeghers syndrome and emphasize the importance of genetic counseling of these patients as well as the adequate sampling of surgical specimens for early detection and treatment.

No abstract